You are here

  • Home
  • Archive
  • Volume 77, Issue 5
  • Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Article info

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Authors

  1. Correspondence to Dr Benjamin Hsu, Janssen Research & Development, Spring House, PA 19477, USA; BHsu{at}its.jnj.com
View Full Text

Citation

Taylor PC, Schiff MH, Wang Q, et al
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study
Annals of the Rheumatic Diseases 2018;77:658-666.

Publication history

  • Received October 4, 2017
  • Revised January 8, 2018
  • Accepted January 9, 2018
  • First published February 26, 2018.
Online issue publication 
October 31, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.